China Pharma Holdings (CPHI) EBITDA Margin (2010 - 2026)
China Pharma Holdings (CPHI) reported EBITDA Margin of 72.14% for Q1 2026, down 367.0% on a YoY basis from 27.02% in Q1 2025, and up 15.3% quarter-over-quarter from 85.18% in Q4 2025.
China Pharma Holdings (CPHI) EBITDA Margin (2010 - 2026) Analysis & Trends
China Pharma Holdings has reported EBITDA Margin for 17 years, with the latest figure at 72.14% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 367.0% year-over-year to 72.14%; the trailing twelve-month figure through Mar 2026 stood at 71.55% (up 3715.0% YoY), and the FY2025 full-year result was 70.57%, up 3694.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 72.14%, up from 85.18% in the prior quarter.
- The five-year high for EBITDA Margin was 13.81% in Q1 2023, with the low at 160.4% in Q2 2024.
- Historically, EBITDA Margin has averaged 74.67% across 5 years, with a median of 71.36% in 2024.
- Annual changes were most pronounced in 2024 — EBITDA Margin plunged 7441 bps — and 2025, when it jumped 11087 bps.
- China Pharma Holdings' EBITDA Margin stood at 37.0% in 2022, then plunged by 39 bps to 51.46% in 2023, then sank by 145 bps to 125.87% in 2024, then jumped by 32 bps to 85.18% in 2025, then rose by 15 bps to 72.14% in 2026.
- The last three EBITDA Margin figures came in at 72.14% (Q1 2026), 85.18% (Q4 2025), and 78.57% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -170.35% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.25% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | China Pharma Holdings | 18.87 Mn | 18.70 Mn | 285,487.00 | -72.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -72.14% |
| Dec 31, 2025 | -85.18% |
| Sep 30, 2025 | -78.57% |
| Jun 30, 2025 | -49.53% |
| Mar 31, 2025 | -68.47% |
| Dec 31, 2024 | -125.87% |
| Sep 30, 2024 | -89.10% |
| Jun 30, 2024 | -160.40% |
| Mar 31, 2024 | -71.36% |
| Dec 31, 2023 | -51.46% |
| Sep 30, 2023 | -39.16% |
| Jun 30, 2023 | -101.72% |
| Mar 31, 2023 | -13.81% |
| Dec 31, 2022 | -37.00% |
| Sep 30, 2022 | -70.69% |
| Jun 30, 2022 | -93.94% |
| Mar 31, 2022 | -60.96% |
| Dec 31, 2021 | -28.97% |
| Sep 30, 2021 | -43.68% |
| Jun 30, 2021 | -26.55% |